← Back to Clinical Trials
Recruiting NCT05283265

NCT05283265 Neurophysiological Mechanisms of Language Comprehension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05283265
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition Language Disorders
Study Type INTERVENTIONAL
Enrollment 153 participants
Start Date 2022-04-08
Primary Completion 2026-10-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Sentence TypeDirect brain stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 153 participants in total. It began in 2022-04-08 with a primary completion date of 2026-10-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

First, in a recording-only self-paced reading experiment, patients with epilepsy undergoing intracranial monitoring for clinical purposes will read or listen to sentences presented to them one word at time while the investigators simultaneously record neural activity through intracranial electrodes that are implanted for clinical purposes (see subject populations). At the end of the sentence, the subjects have to indicate how they comprehended the sentence by selecting which of several pictures matches the sentence they just read. Behavioral measures that the investigators record and analyze are their response times to advance to each next word in the sentence, and which picture they chose for each sentence. These behavioral measures are compared against the neural activity simultaneously recorded as they are made. Then, in a later session, the same participants will participate in a task-related stimulation experiment. This follows the exact same design as the recording-only reading experiment, the only difference is that on some trials, at controlled moments during the sentence presentation intracranial electrical stimulation is delivered through adjacent intracranial electrode contacts. The investigators will examine the effect of this stimulation on the subjects comprehension of the sentences measured by their behavior, and on the simultaneously recorded neural activity.

Eligibility Criteria

Inclusion Criteria: * Age 18 and older * Undergoing standard of care stereo Electro Encephalogram (sEEG) or Electro-Corticogram (ECoG) monitoring * Able to competently perform control trials of the task Exclusion Criteria: * Age less than 18 years * Unable to competently perform control trials of the task

Contact & Investigator

Central Contact

Matthew Nelson, PhD

✉ matthewnelson@uabmc.edu

📞 2059346717

Principal Investigator

Matthew Nelson, PhD

PRINCIPAL INVESTIGATOR

The University of Alabama at Birmingham

Frequently Asked Questions

Who can join the NCT05283265 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Language Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05283265 currently recruiting?

Yes, NCT05283265 is actively recruiting participants. Contact the research team at matthewnelson@uabmc.edu for enrollment information.

Where is the NCT05283265 trial being conducted?

This trial is being conducted at Birmingham, United States.

Who is sponsoring the NCT05283265 clinical trial?

NCT05283265 is sponsored by University of Alabama at Birmingham. The principal investigator is Matthew Nelson, PhD at The University of Alabama at Birmingham. The trial plans to enroll 153 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology